unknown
Stage
1
Investors
About
Deka Biosciences develops disease-specific “Diakines,” therapeutic constructs that combine dual and complementary cytokines intended to improve pharmacokinetics and pharmacodynamics by promoting targeted accumulation of cytokines in affected tissues and by tailoring immune responses.
Explore Deka Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.